Modern approaches in the medical and social rehabilitation of patients with chronic heart failure

Abstract

Currently, chronic heart failure (CHF) is one of the most relevant health and social problems. This is stipulated by its high prevalence, morbidity growth (annually develops about 0.5 million new cases) and poor prognosis. CHF is the final stage of cardiovascular continuum, which causes most of the mortality and high rates of disability in the population. Treatment of CHF requires considerable spending in many countries around the world - up to 1 to 2 % ofall health care facilities and 10.8% of the total budget allotted to the treatment of cardiovascular diseases. Approximately 70 % of this amount is spent on the treatment ofpatients hospitalized in the hospital with worsening heart failure. Low survival at this stage, on the one hand, and the high costs of hospital care, on the other - the need to define the optimization approaches to medical and social rehabilitation of patients with chronic heart failure. This article, the first of a planned series of articles that will highlight current issues of epidemiology, etiopathogenetic formation, clinical expert diagnosis, therapy and prevention of heart failure.

Keywords

chronic heartfailure / disability and death / medical and social rehabilitation / optimization of treatment results

References

[1] ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, 2012. Eur Heart J. 2012; 33: 1787-847.

[2] Smith W.M. Epidemiology of congestive heart failure. Am. J. Cardiol. 1985; 55: 3A-8.

[3] Gibson T.C., White K.L., Klainer L.M. The prevalence of congestive heart failure in two rural communities. J. Chron. Dis. 1966; 19: 141-52.

[4] Ho K.K., Pinsky J.L., Kannel W.B. et al. The epidemiology of heart failure: Framingham Study. J. Am. Coll. Cardiol. 1993; 22(Suppl. A): 6А-13.

[5] Thom T., Haase N., Rosamond W. et al. Heart disease and stroke statistics-2006 Update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006; 113: e85-151.

[6] Агеев Ф.Т., Беленков Ю.Н., Фомин И.В. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации - данные ЭПОХА-ХСН. Журнал сердечная недостаточность. 2006;7 (1): 112-5.

[7] Мареев В.Ю., Даниелян М.О., Беленков Ю.Н. От имени рабочей группы исследования ЭПОХА-О-ХСН. Сравнительная характеристика больных с ХСН в зависимости от величины ФВ по результатам Российского многоцентрового исследования ЭПОХА-О-ХСН. Журнал сердечная недостаточность. 2006;7 (4):164-71.

[8] Национальные рекомендации ВНОК И ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал сердечная недостаточность. 2010; 11[1(57)].

[9] Клинические рекомендации. Диагностика и лечение хронической и острой сердечной недостаточности. М.: МЗ РФ; 2013.

[10] 2013 ESH/ESC Guidelines for themanagement of arterial hypertension TheTask Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. nypertension. 2013, 31 (7): 1324.

[11] Фомин И.В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. В кн.: Агеев Ф.Т. и др. Хроническая сердечная недостаточность. М.: ГЭОТАР-Медиа; 2010:7-77.

[12] Cleland J.G., Swedberg K., Follath F. et al. The EuroHeart Failure survey programme a survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur. Heart. J. 2003; 24 (5): 442-63.

[13] Кэмм А.Дж., Люшер Т.Ф., Серруис П.В., ред. Болезни сердца и сосудов. Руководство Европейского общества кардиологов. М.: ГЭОТАР-Медиа; 2011: 851-903.

[14] Bristow M.R. Why does the myocardium fail? Insights from basic science. Lancet. 1998; 352 (Suppl. 1): 8-14.

[15] Мухарлямов Н.М. Ранние стадии недостаточности кровообращения и механизмы ее компенсации. М.: Медицина; 1978.

[16] Национальные рекомендации по диагностике и лечению ХСН (Утверждены съездом кардиологов РФ в октябре 2003 г.). Сердечная недостаточность. 2003;4 (6): 276-97.

[17] Cohn L.H., Rizzo R.J., Adams D.H. et al. The effect of pathophysiology on the surgical treatment of ischemic mitral regurgitation: operative and late risks of repair versus replacement. Eur. J. Cardiothorac. Surg. 1995; 9: 568-74.

[18] Owan T.E., Hodge D.O., Herges R.M. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 2006; 355 (3): 251-9.

[19] Rafael C.E., Whinnet Z.I., Davies J.E.,Fontana M., Ferenci E.A, Manisty C.H. et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart. 2009; 95: 56-62.

RIGHTS & PERMISSIONS

Eco-Vector